Figure 6From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]CRP and fibrinogen up to 6 months following trial entry, according to allocated trial treatment. (a) CRP; and (b) fibrinogen.Back to article page